|
1
|
Romero I and Bast RC Jr: Minireview: human
ovarian cancer: biology, current management, and paths to
personalizing therapy. Endocrinology. 153:1593–1602. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lopez J, Banerjee S and Kaye SB: New
developments in the treatment of ovarian cancer - future
perspectives. Ann Oncol. 24:(Suppl 10). X69–X76. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim A, Ueda Y, Naka T and Enomoto T:
Therapeutic strategies in epithelial ovarian cancer. J Exp Clin
Cancer Res. 31:142012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlay J, Parkin DM and Steliarova-Foucher
E: Estimates of cancer incidence and mortality in Europe in 2008.
Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leitao MM Jr and Chi DS: Surgical
management of recurrent ovarian cancer. Semin Oncol. 36:106–111.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leszczyniecka M, Roberts T, Dent P, Grant
S and Fisher PB: Differentiation therapy of human cancer: Basic
science and clinical applications. Pharmacol Ther. 90:105–156.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang ME, Ye YC, Chen SR, Chai JR, Lu JX,
Zhoa L, Gu LJ and Wang ZY: Use of all-trans retinoic acid in the
treatment of acute promyelocytic leukemia. Blood. 72:567–572.
1988.PubMed/NCBI
|
|
8
|
Kinjo K, Kizaki M, Muto A, Fukuchi Y,
Umezawa A, Yamato K, Nishihara T, Hata J, Ito M, Ueyama Y, et al:
Arsenic trioxide (As2O3)-induced apoptosis
and differentiation in retinoic acid-resistant acute promyelocytic
leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia.
14:431–438. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamashita Y, Shimada M, Harimoto N,
Rikimaru T, Shirabe K, Tanaka S and Sugimachi K: Histone
deacetylase inhibitor trichostatin A induces cell-cycle
arrest/apoptosis and hepatocyte differentiation in human hepatoma
cells. Int J Cancer. 103:572–576. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rosato RR and Grant S: Histone deacetylase
inhibitors in clinical development. Expert Opin Investig Drugs.
13:21–38. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Buchwald M, Krämer OH and Heinzel T: HDACi
- targets beyond chromatin. Cancer Lett. 280:160–167. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Eickhoff B, Germeroth L, Stahl C, Köhler
G, Rüller S, Schlaak M and van der Bosch J: Trichostatin A-mediated
regulation of gene expression and protein kinase activities:
Reprogramming tumor cells for ribotoxic stress-induced apoptosis.
Biol Chem. 381:1127–1132. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Freudlsperger C, Burnett JR, Friedman JA,
Kannabiran VR, Chen Z and Van Waes C: EGFR-PI3K-AKT-mTOR signaling
in head and neck squamous cell carcinomas: Attractive targets for
molecular-oriented therapy. Expert Opin Ther Targets. 15:63–74.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lassus H, Sihto H, Leminen A, Joensuu H,
Isola J, Nupponen NN and Butzow R: Gene amplification, mutation,
and protein expression of EGFR and mutations of ERBB2 in serous
ovarian carcinoma. J Mol Med (Berl). 84:671–681. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shao G, Wang J, Li Y, Liu X, Xie X, Wan X,
Yan M, Jin J, Lin Q, Zhu H, et al: Lysine-specific demethylase 1
mediates epidermal growth factor signaling to promote cell
migration in ovarian cancer cells. Sci Rep. 5:153442015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Y, Wan X, Wei Y, Liu X, Lai W, Zhang L,
Jin J, Wu C, Shao Q, Shao G, et al: LSD1-mediated epigenetic
modification contributes to ovarian cancer cell migration and
invasion. Oncol Rep. 35:3586–3592. 2016.PubMed/NCBI
|
|
17
|
Kaestner KH: The FoxA factors in
organogenesis and differentiation. Curr Opin Genet Dev. 20:527–532.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jeong JW, Kwak I, Lee KY, Kim TH, Large
MJ, Stewart CL, Kaestner KH, Lydon JP and DeMayo FJ: Foxa2 is
essential for mouse endometrial gland development and fertility.
Biol Reprod. 83:396–403. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Akimoto T, Hunter NR, Buchmiller L, Mason
K, Ang KK and Milas L: Inverse relationship between epidermal
growth factor receptor expression and radiocurability of murine
carcinomas. Clin Cancer Res. 5:2884–2890. 1999.PubMed/NCBI
|
|
20
|
Wang LT, Liou JP, Li YH, Liu YM, Pan SL
and Teng CM: A novel class I HDAC inhibitor, MPT0G030, induces cell
apoptosis and differentiation in human colorectal cancer cells via
HDAC1/PKCδ and E-cadherin. Oncotarget. 5:5651–5662. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu H, Wu H, Wang Y, Wang Y, Wu X, Ju S
and Wang X: Inhibition of class II histone deacetylase blocks
proliferation and promotes neuronal differentiation of the
embryonic rat neural progenitor cells. Acta Neurobiol Exp (Wars).
72:365–376. 2012.PubMed/NCBI
|
|
22
|
Kretsovali A, Hadjimichael C and
Charmpilas N: Histone deacetylase inhibitors in cell pluripotency,
differentiation, and reprogramming. Stem Cells Int.
2012:1841542012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cruz FD and Matushansky I: Solid tumor
differentiation therapy - is it possible? Oncotarget. 3:559–567.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ciurea ME, Georgescu AM, Purcaru SO,
Artene SA, Emami GH, Boldeanu MV, Tache DE and Dricu A: Cancer stem
cells: Biological functions and therapeutically targeting. Int J
Mol Sci. 15:8169–8185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kwon MJ and Shin YK: Regulation of ovarian
cancer stem cells or tumor-initiating cells. Int J Mol Sci.
14:6624–6648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li X, Wang J, Xu Z, Ahmad A, Li E, Wang Y,
Qin S and Wang Q: Expression of Sox2 and Oct4 and their clinical
significance in human non-small-cell lung cancer. Int J Mol Sci.
13:7663–7675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ge N, Lin HX, Xiao XS, Guo L, Xu HM, Wang
X, Jin T, Cai XY, Liang Y, Hu WH, et al: Prognostic significance of
Oct4 and Sox2 expression in hypopharyngeal squamous cell carcinoma.
J Transl Med. 8:942010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin H, Sun LH, Han W, He TY, Xu XJ, Cheng
K, Geng C, Su LD, Wen H, Wang XY, et al: Knockdown of OCT4
suppresses the growth and invasion of pancreatic cancer cells
through inhibition of the AKT pathway. Mol Med Rep. 10:1335–1342.
2014.PubMed/NCBI
|
|
29
|
Bang SY, Kwon SH, Yi SH, Yi SA, Park EK,
Lee JC, Jang CG, You JS, Lee SH and Han JW: Epigenetic activation
of the Foxa2 gene is required for maintaining the potential of
neural precursor cells to differentiate into dopaminergic neurons
after expansion. Stem Cells Dev. 24:520–533. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang X, Lu F, Wang J, Yin F, Xu Z, Qi D,
Wu X, Cao Y, Liang W, Liu Y, et al: Pluripotent stem cell protein
Sox2 confers sensitivity to LSD1 inhibition in cancer cells. Cell
Rep. 5:445–457. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sherr CJ and Roberts JM: CDK inhibitors:
Positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Weiss RH: p21Waf1/Cip1 as a
therapeutic target in breast and other cancers. Cancer Cell.
4:425–429. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jackson RJ, Adnane J, Coppola D, Cantor A,
Sebti SM and Pledger WJ: Loss of the cell cycle inhibitors
p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse
models. Oncogene. 21:8486–8497. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bali A, O'Brien PM, Edwards LS, Sutherland
RL, Hacker NF and Henshall SM: Cyclin D1, p53, and
p21Waf1/Cip1 expression is predictive of poor clinical
outcome in serous epithelial ovarian cancer. Clin Cancer Res.
10:5168–5177. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ahrens TD, Timme S, Hoeppner J, Ostendorp
J, Hembach S, Follo M, Hopt UT, Werner M, Busch H, Boerries M, et
al: Selective inhibition of esophageal cancer cells by combination
of HDAC inhibitors and Azacytidine. Epigenetics. 10:431–445. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou
JL, Feng CR, Fang QH, Wang HH, Zhang PF, et al: The histone
deacetylase inhibitor suberoylanilide hydroxamic acid induces
growth inhibition and enhances taxol-induced cell death in breast
cancer. Cancer Chemother Pharmacol. 66:1131–1140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou C, Qiu L, Sun Y, Healey S, Wanebo H,
Kouttab N, Di W, Yan B and Wan Y: Inhibition of EGFR/PI3K/AKT cell
survival pathway promotes TSA's effect on cell death and migration
in human ovarian cancer cells. Int J Oncol. 29:269–278.
2006.PubMed/NCBI
|
|
38
|
Liu JJ, Lin B, Hao YY, Li FF, Liu DW, Qi
Y, Zhu LC, Zhang SL and Iwamori M: Lewis(y) antigen stimulates the
growth of ovarian cancer cells via regulation of the epidermal
growth factor receptor pathway. Oncol Rep. 23:833–841.
2010.PubMed/NCBI
|
